65 related articles for article (PubMed ID: 21224372)
1. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy.
Fregni G; Perier A; Pittari G; Jacobelli S; Sastre X; Gervois N; Allard M; Bercovici N; Avril MF; Caignard A
Clin Cancer Res; 2011 May; 17(9):2628-37. PubMed ID: 21224372
[TBL] [Abstract][Full Text] [Related]
2. Updates in adjuvant systemic therapy for melanoma.
Kwak M; Farrow NE; Salama AKS; Mosca PJ; Hanks BA; Slingluff CL; Beasley GM
J Surg Oncol; 2019 Jan; 119(2):222-231. PubMed ID: 30481375
[TBL] [Abstract][Full Text] [Related]
3. CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells.
Davenport AJ; Jenkins MR; Cross RS; Yong CS; Prince HM; Ritchie DS; Trapani JA; Kershaw MH; Darcy PK; Neeson PJ
Cancer Immunol Res; 2015 May; 3(5):483-94. PubMed ID: 25711536
[TBL] [Abstract][Full Text] [Related]
4. The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies.
Rahimi A; Malakoutikhah Z; Rahimmanesh I; Ferns GA; Nedaeinia R; Ishaghi SMM; Dana N; Haghjooy Javanmard S
Cancer Cell Int; 2023 Dec; 23(1):312. PubMed ID: 38057843
[TBL] [Abstract][Full Text] [Related]
5. Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia.
Tenuta M; Pandozzi C; Sciarra F; Campolo F; Gelibter AJ; Sirgiovanni G; Cortesi E; Lenzi A; Isidori AM; Sbardella E; Venneri MA
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509255
[TBL] [Abstract][Full Text] [Related]
6. The application of autologous cancer immunotherapies in the age of memory-NK cells.
Lizana-Vasquez GD; Torres-Lugo M; Dixon RB; Powderly JD; Warin RF
Front Immunol; 2023; 14():1167666. PubMed ID: 37205105
[TBL] [Abstract][Full Text] [Related]
7. Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function.
Li JH; O'Sullivan TE
Front Immunol; 2021; 12():816658. PubMed ID: 35082797
[TBL] [Abstract][Full Text] [Related]
8. NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma.
Garofalo C; De Marco C; Cristiani CM
Front Oncol; 2021; 11():754541. PubMed ID: 34712615
[TBL] [Abstract][Full Text] [Related]
9. Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy.
Rethacker L; Roelens M; Bejar C; Maubec E; Moins-Teisserenc H; Caignard A
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810032
[TBL] [Abstract][Full Text] [Related]
10. Targeting NK Cells to Enhance Melanoma Response to Immunotherapies.
Lee H; Da Silva IP; Palendira U; Scolyer RA; Long GV; Wilmott JS
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33802954
[TBL] [Abstract][Full Text] [Related]
11. The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment.
Vorontsova A; Kan T; Raviv Z; Shaked Y
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33276524
[TBL] [Abstract][Full Text] [Related]
12. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
Frazao A; Rethacker L; Jeudy G; Colombo M; Pasmant E; Avril MF; Toubert A; Moins-Teisserenc H; Roelens M; Dalac S; Maubec E; Caignard A
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912923
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Resistance to NK Cell Immunotherapy.
Sordo-Bahamonde C; Vitale M; Lorenzo-Herrero S; López-Soto A; Gonzalez S
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272610
[TBL] [Abstract][Full Text] [Related]
14. NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment.
Frazao A; Rethacker L; Messaoudene M; Avril MF; Toubert A; Dulphy N; Caignard A
Front Immunol; 2019; 10():661. PubMed ID: 30984204
[TBL] [Abstract][Full Text] [Related]
15. Circulating NKp46
Picard E; Godet Y; Laheurte C; Dosset M; Galaine J; Beziaud L; Loyon R; Boullerot L; Lauret Marie Joseph E; Spehner L; Jacquin M; Eberst G; Gaugler B; Le Pimpec-Barthes F; Fabre E; Westeel V; Caignard A; Borg C; Adotévi O
Oncoimmunology; 2019; 8(2):e1527498. PubMed ID: 30713781
[TBL] [Abstract][Full Text] [Related]
16. Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.
Jacquelot N; Pitt JM; Enot DP; Roberti MP; Duong CPM; Rusakiewicz S; Eggermont AM; Zitvogel L
Oncoimmunology; 2017; 6(8):e1299303. PubMed ID: 28919986
[TBL] [Abstract][Full Text] [Related]
17. Increased level and interferon-γ production of circulating natural killer cells in patients with scrub typhus.
Kang SJ; Jin HM; Cho YN; Kim SE; Kim UJ; Park KH; Jang HC; Jung SI; Kee SJ; Park YW
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005815. PubMed ID: 28750012
[TBL] [Abstract][Full Text] [Related]
18. NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.
Messaoudene M; Fregni G; Enot D; Jacquelot N; Neves E; Germaud N; Garchon HJ; Boukouaci W; Tamouza R; Chanal J; Avril MF; Toubert A; Zitvogel L; Rusakiewicz S; Caignard A
Oncoimmunology; 2016; 5(12):e1154251. PubMed ID: 28123867
[TBL] [Abstract][Full Text] [Related]
19. Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.
Bücklein V; Adunka T; Mendler AN; Issels R; Subklewe M; Schmollinger JC; Noessner E
Oncoimmunology; 2016 Jul; 5(7):e1178421. PubMed ID: 27622032
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of a highly immunogenic human renal carcinoma cell line.
Prattichizzo C; Gigante M; Pontrelli P; Stella A; Rocchetti MT; Gigante M; Maiorano E; Herr W; Battaglia M; Gesualdo L; Ranieri E
Int J Oncol; 2016 Aug; 49(2):457-70. PubMed ID: 27278998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
